Graded function of CD80 and CD86 in initiation of T-cell immune response and cardiac allograft survival

Transplant International

Volumn 21, Issue 2, 2008, Pages 163-168

  Xiang, Jianbin ^a   Gu, Xiaodong ^a   Qian, Shiguang ^b   Chen, Zongyou ^a  

^a FUDAN UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CD80; CD86; Dendritic cell; Small interfering RNA

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE PRODUCTION; DENDRITIC CELL; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOSTIMULATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTERFERON TYPE II; INTERLEUKINS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PHENOTYPE; T-LYMPHOCYTES;

EID: 38049153066     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00590.x     Document Type: Article

References (20)

1. Manzotti CN, Liu MK, Burke F, Dussably L, Zheng Y, Sansom DM. Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. Eur J Immunol 2006 36 : 1413.
2. Odobasic D, Kitching AR, Tipping PG, Holdsworth SR. CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms. Kidney Int 2005 68 : 584.
3. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995 181 : 1145.
4. Gu X, Xiang J, Yao Y, Chen Z. Effects of RNA interference on CD80 and CD86 expression in bone marrow-derived murine dendritic cells. Scand J Immunol 2006 64 : 588.
5. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999 223 : 77.
6. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002 26 : 199.
7. Campbell TN, Choy FY. RNA interference: past, present and future. Curr Issues Mol Biol 2005 7 : 1.
8. Gaither A, Iourgenko V. RNA interference technologies and their use in cancer research. Curr Opin Oncol 2007 19 : 50.
9. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003 21 : 685.
10. Vasu C, Wang A, Gorla SR, Kaithamana S, Prabhakar BS, Holterman MJ. CD80 and CD86 C domains play an important role in receptor binding and co-stimulatory properties. Int Immunol 2003 15 : 167.
11. Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol 2003 24 : 314.
12. Slavik JM, Hutchcroft JE, Bierer BE. CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28. J Biol Chem 1999 274 : 3116.
13. Lang TJ, Nquven P, Peach R, Gause WC, Via CS. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function. J Immunol 2002 168 : 3786.
14. Cao MD, Chen ZD, Xing Y. Gamma irradiation of human dendritic cells influences proliferation and cytokine profile of T cells in autologous mixed lymphocyte reaction. Cell Biol Int 2004 28 : 223.
15. Bonham CA, Peng L, Liang X, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002 169 : 3382.
16. Giannoukakis N, Bonham CA, Qian S, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther 2000 1 : 430.
17. Liang X, Lu L, Chen Z, et al. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation 2003 76 : 721.
18. Schweitzer AN, Sharpe AH. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol 1998 161 : 2762.
19. Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, Sansom DM. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 2004 172 : 2778.
20. Snanoudj R, de Preneuf H, Creput C, et al. Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 2006 19 : 693.